UK markets closed

Capricor Therapeutics, Inc. (CAPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.79+0.02 (+0.30%)
At close: 04:00PM EDT
6.92 +0.13 (+1.91%)
After hours: 06:50PM EDT

Capricor Therapeutics, Inc.

10865 Road to the Cure
Suite 150
San Diego, CA 92121
United States
858 727 1755
https://www.capricor.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees101

Key executives

NameTitlePayExercisedYear born
Dr. Frank Isaac Litvack FACC, M.D.Executive Chairman of the Board120kN/A1956
Dr. Linda Marbán Ph.D.Co-Founder, President, CEO & Director282.3kN/A1963
Mr. Anthony J. Bergmann M.B.A.CFO & Corporate Treasurer459.15kN/A1986
Ms. Karen G. KrasneyExecutive VP, General Counsel & Secretary434.53kN/A1953
Dr. Eduardo MarbánCo-Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Kristi A. H. Elliott Ph.D.Chief Science OfficerN/AN/AN/A
Catherine Lee KelleherConsultantN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.

Corporate governance

Capricor Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.